Fiche publication
Date publication
mars 2021
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr REPPEL Loïc
Tous les auteurs :
Carnoy S, Beaumont JL, Kanouni T, Parquet N, Beauvais D, Hequet O, Kanold J, Ballot C, Mialou V, Reppel L, Damaj G, Yakoub-Agha I, Chabannon C
Lien Pubmed
Résumé
Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant cells. In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta™) is the treatment of relapsed/refractory DLBCL and mediastinal B-cell lymphoma. Both products are "living drugs" and genetically modified autologous T cells directed against CD19 which is an antigen expressed throughout B lymphoid differentiation and on many B malignancies. This collaborative work - part of a series of expert works on the topic - aims to provide practical advice to assist collection facilities that procure the starting material i.e. blood mononuclear cells for autologous CAR T-cell manufacturing.
Mots clés
B-cell acute lymphoblastic leukemia, CAR T-cells, Cytapheresis, Cytaphérèse, Diffuse large B-cell lymphoma, Leucémie aiguë lymphoblastique B, Lymphome diffus à grandes cellules B
Référence
Bull Cancer. 2021 03;108(3):295-303
